Avacta Group plc announces the opening on 5 April 2023 of the first two clinical investigator sites for the phase 1 clinical trial of AVA6000 under its US Investigational New Drug Application.The two sites, Memorial Sloan Kettering Cancer Center in New York and Fred Hutch Cancer Center in Seattle, are now open for patient enrolment to ALS-6000-101.
